Thermo Fisher Scientific Stock Berne S.E.
Equities
TFS
US8835561023
Advanced Medical Equipment & Technology
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
514.5 CHF | -0.35% | -0.35% | +19.58% |
Sales 2024 * | 43.02B 39.25B 58.7B | Sales 2025 * | 46.1B 42.06B 62.89B | Capitalization | 223B 203B 304B |
---|---|---|---|---|---|
Net income 2024 * | 6.15B 5.61B 8.38B | Net income 2025 * | 6.97B 6.36B 9.51B | EV / Sales 2024 * | 5.73 x |
Net Debt 2024 * | 23.49B 21.43B 32.05B | Net Debt 2025 * | 19.14B 17.46B 26.11B | EV / Sales 2025 * | 5.25 x |
P/E ratio 2024 * |
36
x | P/E ratio 2025 * |
30.8
x | Employees | - |
Yield 2024 * |
0.26% | Yield 2025 * |
0.28% | Free-Float | 86.04% |
Latest transcript on Thermo Fisher Scientific
1 day | -0.35% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Casper
CEO | Chief Executive Officer | 56 | 01-10-31 |
Director of Finance/CFO | 57 | 01-05-31 | |
Ryan Snyder
CTO | Chief Tech/Sci/R&D Officer | - | 18-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marc Casper
CEO | Chief Executive Officer | 56 | 01-10-31 |
C. Harris
BRD | Director/Board Member | 67 | 12-03-29 |
Ruby Chandy
BRD | Director/Board Member | 62 | 22-02-28 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.83% | 195B | |
+18.87% | 144B | |
+30.03% | 111B | |
+2.32% | 65.19B | |
+14.15% | 53.02B | |
+2.68% | 50.28B | |
+6.60% | 44.15B | |
+1.85% | 36.45B | |
+20.43% | 31.33B |
- Stock Market
- Equities
- TMO Stock
- TFS Stock